NEW YORK, March 01, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Cnova N.V. securities (NASDAQ:CNV) from November 19, 2014 through December 18, 2015, inclusive (the “Class Period”) of the important March 21, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Cnova investors under the federal securities laws.
To join the Cnova class action, go to the firm’s website at http://rosenlegal.com/cases-807.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Cnova overstated net sales; (2) Cnova failed to properly write-off the value of certain returned items; (3) there was a material discrepancy in accounts receivable related to the damaged/returned items; (4) Cnova’s EBIT was overstated; (5) Cnova lacked adequate internal controls; and (6) as a result, defendants’ statements about Cnova’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-807.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



